Patient characteristics for study comparing blasts in MDS
| Characteristic . | No. of patients . |
|---|---|
| Sex, M/F | 35/26 |
| Median age, y (range) | 70 (32-88) |
| World Health Organization subtype | |
| RCUD | 9 |
| RCMD | 6 |
| RAEB-1 | 5 |
| RAEB-2 | 9 |
| AL-MDS | 32 |
| IPSS category* | |
| Low | 6 |
| Intermediate-1 | 9 |
| Intermediate-2 | 10 |
| High | 15 |
| Unknown | 1 |
| Characteristic . | No. of patients . |
|---|---|
| Sex, M/F | 35/26 |
| Median age, y (range) | 70 (32-88) |
| World Health Organization subtype | |
| RCUD | 9 |
| RCMD | 6 |
| RAEB-1 | 5 |
| RAEB-2 | 9 |
| AL-MDS | 32 |
| IPSS category* | |
| Low | 6 |
| Intermediate-1 | 9 |
| Intermediate-2 | 10 |
| High | 15 |
| Unknown | 1 |
MDS indicates myelodysplastic syndromes; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts; AL-MDS, acute myeloid leukemia transformed from MDS; and IPSS, International Prognostic Scoring System.
Not applicable for patients whose bone marrow contained 30% or more blasts.